Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years.
The total duration of the study per participant will be approximately 30 days, including:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Regular intake of nicotine more than 10 mg per day and unable to stop smoking during the study (occasional smoker can be enrolled).
History or presence of drug or alcohol abuse.
If participants with severe renal impairment:
If participants with normal renal function
Primary purpose
Allocation
Interventional model
Masking
16 participants in 2 patient groups
Loading...
Central trial contact
Trial Transparency email recommended (Toll free for US & Canada)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal